The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Commentary

Tom Huizinga*, Peter Nigrovic, Eric Ruderman, Hendrik Schulze-Koops

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)28-29
Number of pages2
JournalInternational Journal of Advances in Rheumatology
Volume9
Issue number1
StatePublished - Dec 1 2011

ASJC Scopus subject areas

  • Rheumatology

Cite this